| Literature DB >> 29416640 |
Ji Young Park1, Ae Lee Jeong1, Hyun Jeong Joo1, Sora Han1, So-Hyun Kim2, Hye-Youn Kim2, Jong-Seok Lim1, Myeong-Sok Lee1, Hyung-Kyoon Choi2, Young Yang1.
Abstract
Circulating tumor cells (CTCs) are essential for the establishment of distant metastasis. Numerous studies have characterized CTCs as metastatic precursors; however, the molecular nature of CTCs has not been completely revealed yet due to the low number of CTCs in the blood stream. As an alternative approach, we developed a long-term suspension cell culture model using human breast cancer cell lines to mimic CTCs. We found that more than 40 passaged suspension cells acquired the ability to enhance metastasis like cancer stem cells. To identify molecular changes acquired during the suspension cell culture, we analyzed metabolic and lipidomic profiles as well as transcriptome in MDA-MB-468 suspension cells. Glutamate and leucine levels increased in suspension cells, and cholesterol synthesis pathway was altered. The inhibition of glutamate metabolic pathway decreased the proliferation of suspension cells compared to that of adherent cells. In the lipidomic profile, PC species containing long chain and polyunsaturated fatty acids increased in suspension cells and these species could be authentic and specific biomarkers for highly metastatic cancers. As this CTC-mimicking suspension cell culture model may easily apply to various types of cancer, we suggest this model as a great tool to develop therapeutic targets and drugs to eradicate metastatic cancer cells.Entities:
Keywords: lipidomic profile; metabolic profile; metastasis; suspension cells
Year: 2017 PMID: 29416640 PMCID: PMC5787494 DOI: 10.18632/oncotarget.23079
Source DB: PubMed Journal: Oncotarget ISSN: 1949-2553
Figure 1Phenotypic and genotypic analysis of adherent and suspension MDA-MB-468 cells
(A) Adherent and suspension cells were photographed. (B) Number of adherent and suspension cells were directly counted at the indicated day. (C) Cell cycle of adherent and suspension cells was analyzed using flow cytometry at the indicated day. (D) Total RNAs were isolated, and EMT and CSCs marker genes were amplified using RT-PCR. (E) Stably expressing luciferase MDA-MB-468 adherent and suspension cells were injected into the mammary fat pad of athymic nu/nu mice and the in vivo bioluminescent signal was quantified using IVIS Lumina XRMS. Representative in vivo images of adherent or suspension cells injected mice and a dot plot comparing the bioluminescent signal in each group (mean ± SEM, n = 6) are shown. *p < 0.05; two-tailed Mann Whitney t-test (F) Representative images of lung and liver tissue sections staining with vimentin in two groups of animals are shown (Scale bar = 100 µm). (G) The number of mice showing mammary tumor formation and metastases were indicated. AD, adherent cells; SUS, suspension cells.
Figure 2Principal component analysis (PCA) score plot derived from (A) GC-MS data and (B) nanoESI-MS data of adherent and suspension cells. PC1, principal component 1; PC2, principal component 2. AD, adherent cells; SUS, suspension cells.
Metabolic profiles of adherent and suspension MDA-MB-468 human breast cancer cells using GC-M
| Compounda | RT | Mass fragment (m/z)b | Relative intensitiesc | TMSd | |
|---|---|---|---|---|---|
| Adherent | Suspension | ||||
| Alcohols | |||||
| Arabitol*** | 21.61 | 103, 305, 217, 307 | 0.91 ± 0.23 | 0.26 ± 0.10 | 3 |
| Myo-inositol*** | 28.93 | 191, 217, 305, 318 | 39.38 ± 4.19 | 20.85 ± 3.82 | 6 |
| Glucitol | 26.25 | 103, 205, 217, 319 | 0.23 ± 0.04 | 0.27 ± 0.08 | 6 |
| Amino acids | |||||
| Alanine | 7.02 | 116, 133, 191, 218 | 6.04 ± 0.72 | 5.38 ± 0.99 | 2 |
| Asparagine*** | 19.22 | 116, 130, 159, 261 | 1.39 ± 0.16 | 0.19 ± 0.05 | 2 |
| Aspartic acid*** | 15.07 | 117, 130, 160, 245 | 2.73 ± 0.29 | 1.64 ± 0.35 | 2 |
| Glutamic acid*** | 19.76 | 128, 156, 246, 348 | 9.28 ± 2.08 | 21.40 ± 8.45 | 3 |
| Glycine** | 7.48 | 59, 102, 176, 204 | 23.26 ± 7.07 | 14.06 ± 2.36 | 2 |
| 12.02 | 133, 174, 248, 276 | 3 | |||
| Hydroxyproline*** | 16.29 | 75, 103, 158, 260 | 1.98 ± 0.21 | 0.50 ± 0.17 | 2 |
| Isoleucine | 8.84 | 86, 130, 146, 188 | 7.73 ± 1.24 | 6.75 ± 1.38 | 1 |
| Leucine*** | 8.32 | 86, 103, 146, 188 | 5.65 ± 1.06 | 10.52 ± 2.59 | 1 |
| Methionine*** | 14.72 | 56, 61, 104, 221 | 2.35 ± 0.34 | 1.12 ± 0.43 | 1 |
| Phenylalanine*** | 18.00 | 91, 120, 146, 222 | 4.80 ± 0.54 | 1.68 ± 0.28 | 1 |
| Proline | 8.78 | 70, 75, 103, 172 | 9.56 ± 2.07 | 7.31 ± 3.36 | 1 |
| Pyroglutamic acid*** | 17.37 | 133, 156, 230, 258 | 24.05 ± 3.14 | 5.66 ± 1.78 | 2 |
| Serine*** | 10.83 | 103, 116, 132, 234 | 9.82 ± 1.57 | 6.82 ± 1.22 | 2 |
| Threonine*** | 11.76 | 117,130, 158, 219 | 6.76 ± 0.98 | 3.20 ± 0.61 | 2 |
| Tyrosine*** | 25.34 | 179, 208, 219, 310 | 21.59 ± 2.09 | 7.37 ± 0.86 | 2 |
| 26.36 | 100, 179, 218, 280 | 3 | |||
| Valine*** | 6.75 | 72, 130, 146, 174 | 14.98 ± 2.47 | 8.68 ± 1.50 | 1 |
| Organic acids | |||||
| Aminomalonic acid*** | 16.16 | 133, 174, 218, 320 | 2.08 ± 0.35 | 1.10 ± 0.27 | 3 |
| Fumaric acid*** | 13.26 | 83, 133, 143, 245 | 1.19 ± 0.12 | 0.54 ± 0.11 | 2 |
| 2-Hydroxyglutaric acid*** | 18.74 | 129, 157, 247, 349 | 0.29 ± 0.03 | 0.09 ± 0.02 | 3 |
| Lactic acid*** | 6.10 | 117, 133,191, 219 | 533.52 ± 69.31 | 353.18 ± 65.13 | 2 |
| Malic acid*** | 16.66 | 133, 233, 245, 335 | 5.91 ± 0.67 | 2.91 ± 0.49 | 3 |
| Fatty acids | |||||
| Palmitic acid | 28.34 | 117, 129, 145, 313 | 0.23 ± 0.06 | 0.25 ± 0.06 | 1 |
| Stearic acid | 31.48 | 117, 129, 145, 341 | 0.22 ± 0.09 | 0.26 ± 0.09 | 1 |
| Sugars | |||||
| Glucose | 25.47 | 103, 191, 204, 217 | 21.16 ± 2.89 | 23.46 ± 7.23 | 5 |
| 25.52 | 160, 205, 217, 319 | 5(1MEOX) | |||
| 27.13 | 103, 191, 204, 217 | 5 | |||
| Glucose-6-phosphate | 32.47 | 129, 299, 357, 387 | 6.09 ± 1.47 | 6.90 ± 1.34 | 6 |
| 33.31 | 204, 299, 315, 387 | 6 | |||
| Glyceric acid*** | 12.68 | 103, 133, 189, 292 | 1.24 ± 0.25 | 0.81 ± 0.19 | 3 |
| Mannaose-6-phosphate*** | 32.30 | 217, 299, 315, 387 | 2.99 ± 0.60 | 6.64 ± 1.35 | 6 |
| Ribose*** | 21.00 | 103, 189, 217, 307 | 1.92 ± 0.27 | 3.05 ± 0.57 | 3(1MEOX) |
| 25.25 | 103, 217, 277, 307 | 4(1MEOX) | |||
| Purine Guanine*** | 29.58 | 99, 264, 352, 367 | ND | 3.34 ± 1.84 | 3 |
| Pyrimidine Uridine*** | 34.31 | 103, 169, 217, 259 | 9.70 ± 1.93 | 2.02 ± 0.48 | 3 |
aAsterisk-superscripts denote statistical significant differences (Student’s t-test; **p < 0.01; ***p < 0.001) among two groups, adherent and suspension MDA-MB-468 human breast cancer cells.
bBold-faced numbers in mass fragment ion mean base peak.
cValues are presented as mean ± standard deviation of technical duplicates on 6 individual biological replicates; ND, not detected.
dNumbers indicate the number of trimethylsilylation (TMS) incorporated upon derivatization; MEOX, methoxyaminated derivative.
Figure 3Suspension cells show an increase in GLS and are susceptible to treatment with GLS inhibitor
(A) Levels of GLS were examined using immunoblot assay. (B) Adherent and suspension cells were plated at a density of 3 × 105 cells per well and cultured for 3 days in the presence of BPTES. Viable cells were counted. *p < 0.05, **p < 0.01, ***p < 0.001; two-tailed Student’s t-test.
Fold changes (suspension/adherent) and p-values of compounds identified from MDA-MB-468 human breast cancer cells
| Compoundsa | Fold change | |
|---|---|---|
| Cer (d18:1/16:0) | 0.33 | 2.07E-03 |
| Cer (d18:1/17:0) | 0.56 | n.s. |
| Cer (d18:1/18:0) | 0.48 | 6.18E-03 |
| PC (14:0/16:0) | 0.68 | 1.64E-06 |
| PC (16:0/16:0) | 1.70 | 1.85E-07 |
| PC (16:0/16:1) | 0.83 | 3.83E-03 |
| PC (16:0/18:1) | 0.98 | n.s. |
| PC (16:1/18:1) | 1.20 | n.s. |
| PC (18:0/22:5) | 1.48 | 4.42E-03 |
| PC (18:1/18:1) | 1.51 | 1.34E-02 |
| PC (18:1/18:2) | 1.69 | 3.17E-03 |
| PC (18:1/20:4) | 1.36 | n.s. |
| PC (18:1/20:5) | 1.76 | 2.46E-02 |
| PE (P-16:0/20:4) | 0.93 | n.s. |
| PE (18:0/18:1) | 0.74 | 1.59E-04 |
| PE (18:0/20:4) | 1.89 | 8.00E-11 |
| PE (18:0/22:5; 18:1/22:4) | 1.45 | 7.47E-06 |
| PE (18:1/18:1) | 0.49 | 9.97E-14 |
| PE (18:1/20:4) | 1.01 | n.s. |
| PG (16:0/18:1) | 0.79 | 1.20E-05 |
| PG (18:0/18:1) | 0.80 | n.s. |
| PG (18:1/18:1) | 0.50 | 8.14E-09 |
| PS (16:0/18:0) | 0.70 | n.s. |
| PS (16:0/18:1; 16:1/18:0) | 0.57 | n.s. |
| PS (16:1/18:1) | 0.47 | n.s. |
| PS (18:0/18:0) | 0.77 | 9.58E-03 |
| PS (18:0/18:1) | 0.60 | 1.62E-03 |
| PS (18:0/20:1) | 1.03 | n.s. |
| PS (18:0/20:3) | 2.44 | 3.45E-09 |
| PS (18:0/20:4) | 3.73 | 4.97E-03 |
| PS (18:0/22:5) | 0.67 | 1.97E-06 |
| PS (18:0/22:6) | 0.97 | n.s. |
| PS (18:1/18:1) | 0.42 | 3.46E-02 |
| PS (18:1/18:2) | 0.78 | n.s. |
| PI (16:0/18:1) | 0.57 | 7.28E-08 |
| PI (16:0/20:4) | 1.41 | 1.63E-07 |
| PI (16:1/18:1) | 0.83 | n.s. |
| PI (18:0/20:3) | 1.29 | 5.07E-07 |
| PI (18:0/20:4) | 1.58 | 2.00E-11 |
| PI (18:1/18:1) | 0.43 | 2.36E-15 |
| PI (18:1/18:2) | 1.12 | 1.07E-02 |
| PI (18:1/20:4) | 0.90 | 2.75E-02 |
aCer, ceramide; PC, phosphatidylcholine; PE, phosphatidylethanolamine; PG, phosphatidylglycerol; PS, phosphatidylserine; PI, phosphatidylinositol.
bn.s., not statistically significant (p < 0.05).
Figure 4Suspension cells show an increase in PCs that have long chain and PUFA
(A) Comparison of the total normalized summed ion abundances for each lipid class. (B) Ratio of the total normalized abundances of long chain versus short chain fatty acids. Fatty acids more than C18 are considered as long chain fatty acids. (C) Ratio of the total normalized abundances of unsaturated versus saturated of fatty acids. PUFA have more than two unsaturated bonds in a fatty acid.
Figure 5Microarray gene ontology (GO) classification
The x-axis indicates the likelihood [−log2 (p-value)] in a category, and the y-axis indicates the different subcategories of (A) biological process and (B) cell component. The GO terms related to lipid metabolism are represented by red boxes.
List of genes related to lipid and sterol metabolism
| GOTerm_BP | Count | Genes | |
|---|---|---|---|
| Sterol Metabolic Process | 4.48E-07 | 35 | CYB5R3, LDLR, MVD, HMGCR, CYP51A1, HMGCS1, APOC1, LSS, ABCA1, C14ORF1, SCARF1, FDFT1, CYP39A1, INSIG2, DHCR7, INSIG1, PCSK9, SCARB1, CAT, NSDHL, DHCR24, SOAT1, EBP, FDPS, FDXR, SIGMAR1, ABCG1, CEL, CYP7B1, APOL1, CYP27A1, SQLE, MVK, IDI1, SC5DL |
| Sterol Biosynthetic Process | 1.08E-06 | 18 | CYB5R3, EBP, MVD, HMGCR, CYP51A1, HMGCS1, FDPS, LSS, C14ORF1, SIGMAR1, FDFT1, SQLE, DHCR7, MVK, IDI1, SC5DL, DHCR24, NSDHL |
| Cholesterol Metabolic Process | 1.39E-06 | 32 | CYB5R3, MVD, LDLR, HMGCR, CYP51A1, HMGCS1, APOC1, LSS, ABCA1, SCARF1, FDFT1, CYP39A1, INSIG2, DHCR7, INSIG1, PCSK9, SCARB1, CAT, NSDHL, DHCR24, SOAT1, EBP, FDPS, FDXR, ABCG1, CEL, CYP7B1, APOL1, CYP27A1, SQLE, MVK, IDI1 |
| Cholesterol Biosynthetic Process | 1.36E-05 | 14 | CYB5R3, EBP, MVD, HMGCR, CYP51A1, FDPS, HMGCS1, LSS, FDFT1, DHCR7, MVK, IDI1, DHCR24, NSDHL |
| Lipid Biosynthetic Process | 1.75E-05 | 74 | ALDH8A1, CYB5R3, GBGT1, HMGCR, EDN1, LSS, ACSS2, C14ORF1, FDFT1, ELOVL1, PECR, ST6GALNAC6, STARD5, CYP39A1, PTGIS, ANG, ELOVL4, ELOVL3, AGPAT9, QKI, ELOVL7, SCD5, PCYT2, FGF2, PIGA, DHCR24, SPTLC3, PIGU, PIGS, CERCAM, SIGMAR1, PNPLA3, TECR, CHPT1, LPCAT4, PLAUR, SQLE, C5ORF4, PLA2G6, MVK, KGFLP1, C5DL, HSD17B11, MVD, CYP51A1, HSD3B7, CHKB, HMGCS1, MIF, ISYNA1, TPI1, CYP27B1, DHCR7, FASN, ETNK2, SCARB1, ACSL3, NSDHL, CPT1B, EBP, MOGAT2, A4GALT, FADS1, SCD, FDXR, FDPS, ACLY, CYP7B1, GGT5, P2RX7, ISPD, MBOAT2, ALOX5, IDI1, MGST2 |
| Steroid Biosynthetic Process | 2.23E-05 | 28 | CYB5R3, HSD17B11, MVD, HMGCR, CYP51A1, HSD3B7, HMGCS1, LSS, C14ORF1, FDFT1, STARD5, CYP39A1, CYP27B1, DHCR7, SCARB1, FGF2, NSDHL, DHCR24, EBP, FDPS, FDXR, SIGMAR1, TECR, CYP7B1, SQLE, MVK, IDI1, SC5DL |
The significantly up-regulated lipid metabolism-related genes in the suspension MDA-MB-468 cells
| Gene | Description | log2(fold_change) |
|---|---|---|
| ALDH8A1 | Aldehyde Dehydrogenase 8 Family Member A1 | 3.8634 |
| SCARF1 | Scavenger Receptor Class F Member 1 | 3.05874 |
| P2RX7 | Purinergic Receptor P2X 7 | 2.76073 |
| ABCG1 | ATP Binding Cassette Subfamily G Member 1 | 2.44505 |
| CYP27B1 | Cytochrome P450 Family 27 Subfamily B Member 1 | 2.23211 |
| MOGAT2 | Monoacylglycerol O-Acyltransferase 2 | 2.14329 |
| EDN1 | Endothelin 1 | 1.96464 |
| CEL | Carboxyl Ester Lipase | 1.75736 |
| CYP39A1 | Cytochrome P450 Family 39 Subfamily A Member 1 | 1.67679 |
| GPAT3 | Glycerol-3-Phosphate Acyltransferase 3 | 1.52103 |
| PIGA | Phosphatidylinositol Glycan Anchor Biosynthesis Class A | 1.44996 |
| INSIG2 | Insulin Induced Gene 2 | 1.37597 |
| PLA2G6 | Phospholipase A2 Group VI | 1.32606 |
| ABCA1 | ATP Binding Cassette Subfamily A Member 1 | 1.30521 |
| STARD5 | StAR Related Lipid Transfer Domain Containing 5 | 1.23634 |
| FGF7P6 | Fibroblast Growth Factor 7 Pseudogene 6 | 1.23373 |
| QKI | KH Domain Containing RNA Binding | 1.07864 |
| SPTLC3 | Serine Palmitoyltransferase Long Chain Base Subunit 3 | 1.0068 |
| ANG | Angiogenin | #N/A |
| CHKB | Choline Kinase Beta | #N/A |
| CPT1B | Carnitine Palmitoyltransferase 1B | #N/A |
The significantly down-regulated lipid metabolism-related genes in the suspension MDA-MB-468 cells
| Gene | Description | log2(fold_change) |
|---|---|---|
| PTGIS | Prostaglandin I2 (Prostacyclin) Synthase | –4.38964 |
| APOC1 | Apolipoprotein C1 | –4.26849 |
| APOL1 | Apolipoprotein L1 | –4.14778 |
| PCSK9 | Proprotein Convertase Subtilisin/Kexin Type 9 | –3.98917 |
| A4GALT | Alpha 1,4-Galactosyltransferase | –3.13062 |
| FAXDC2 | Fatty Acid Hydroxylase Domain Containing 2 | –2.94314 |
| PNPLA3 | Patatin Like Phospholipase Domain Containing 3 | –2.94113 |
| SCD | Stearoyl-CoA Desaturase | –2.85593 |
| FGF2 | Fibroblast Growth Factor 2 | –2.84993 |
| DHCR7 | 7-Dehydrocholesterol Reductase | –2.66095 |
| ETNK2 | Ethanolamine Kinase 2 | –2.61412 |
| ELOVL4 | ELOVL Fatty Acid Elongase 4 | –2.47722 |
| FASN | Fatty Acid Synthase | –2.44083 |
| FADS1 | Fatty Acid Desaturase 1 | –2.19383 |
| INSIG1 | Insulin Induced Gene 1 | –2.19298 |
| EBP | Emopamil Binding Protein (Sterol Isomerase) | –2.18836 |
| MVD | Mevalonate Diphosphate Decarboxylase | –2.13654 |
| ELOVL3 | ELOVL Fatty Acid Elongase 3 | –2.03057 |
| MVK | Mevalonate Kinase | –2.02055 |
| LSS | Lanosterol Synthase (2,3-Oxidosqualene-Lanosterol Cyclase) | –1.91218 |
| IDI1 | Isopentenyl-Diphosphate Delta Isomerase 1 | –1.88897 |
| FDPS | Farnesyl Diphosphate Synthase | –1.84979 |
| LDLR | Low Density Lipoprotein Receptor | –1.82226 |
| C14ORF1 | Chromosome 14 Open Reading Frame 1 | –1.73982 |
| HSD17B11 | Hydroxysteroid 17-Beta Dehydrogenase 11 | –1.72799 |
| CYP27A1 | Cytochrome P450 Family 27 Subfamily A Member 1 | –1.71884 |
| FDXR | Ferredoxin Reductase | –1.70033 |
| FDFT1 | Farnesyl-Diphosphate Farnesyltransferase 1 | –1.68175 |
| GBGT1 | Globoside Alpha-1,3-N-Acetylgalactosaminyltransferase 1 | –1.65937 |
| ST6GALNAC6 | ST6 N-Acetylgalactosaminide Alpha-2,6-Sialyltransferase 6 | –1.63569 |
| SOAT1 | Sterol O-Acyltransferase 1 | –1.62789 |
| GGT5 | Gamma-Glutamyltransferase 5 | –1.6126 |
| ISPD | Isoprenoid Synthase Domain Containing | –1.61245 |
| TECR | Trans-2,3-Enoyl-CoA Reductase | –1.60378 |
| ISYNA1 | Inositol-3-Phosphate Synthase 1 | –1.57524 |
| DHCR24 | 24-Dehydrocholesterol Reductase | –1.56679 |
| LPCAT4 | Lysophosphatidylcholine Acyltransferase 4 | –1.5494 |
| MGST2 | Microsomal Glutathione S-Transferase 2 | –1.5233 |
| PECR | Peroxisomal Trans-2-Enoyl-CoA Reductase | –1.4498 |
| ACLY | ATP Citrate Lyase | –1.43626 |
| SCD5 | Stearoyl-CoA Desaturase 5 | –1.4233 |
| NSDHL | NAD(P) Dependent Steroid Dehydrogenase-Like | –1.42082 |
| CERCAM | Cerebral Endothelial Cell Adhesion Molecule | –1.41546 |
| CYP51A1 | Cytochrome P450 Family 51 Subfamily A Member 1 | –1.3948 |
| ELOVL7 | ELOVL Fatty Acid Elongase 7 | –1.38885 |
| SQLE | Squalene Epoxidase | –1.37995 |
| ACSS2 | Acyl-CoA Synthetase Short-Chain Family Member 2 | –1.35018 |
| MIF | Macrophage Migration Inhibitory Factor (Glycosylation-Inhibiting Factor) | –1.33722 |
| CYP7B1 | Cytochrome P450 Family 7 Subfamily B Member 1 | –1.23914 |
| ALOX5 | Arachidonate 5-Lipoxygenase | –1.2341 |
| PLAUR | Plasminogen Activator, Urokinase Receptor | –1.23365 |
| TPI1 | Triosephosphate Isomerase 1 | –1.20651 |
| PIGU | Phosphatidylinositol Glycan Anchor Biosynthesis Class U | –1.2031 |
| CYB5R3 | Cytochrome B5 Reductase 3 | –1.19764 |
| CHPT1 | Choline Phosphotransferase 1 | –1.19349 |
| SC5DL | Sterol-C5-Desaturase | –1.19039 |
| ACSL3 | Acyl-CoA Synthetase Long-Chain Family Member 3 | –1.18695 |
| PIGS | Phosphatidylinositol Glycan Anchor Biosynthesis Class S | –1.11575 |
| PCYT2 | Phosphate Cytidylyltransferase 2, Ethanolamine | –1.08604 |
| SCARB1 | Scavenger Receptor Class B Member 1 | –1.0724 |
| HMGCR | 3-Hydroxy-3-Methylglutaryl-CoA Reductase | –1.04385 |
| HMGCS1 | 3-Hydroxy-3-Methylglutaryl-CoA Synthase 1 | –1.03708 |
| MBOAT2 | Membrane Bound O-Acyltransferase Domain Containing 2 | –1.02974 |
| HSD3B7 | Hydroxy-Delta-5-Steroid Dehydrogenase, 3 Beta- And Steroid Delta-Isomerase 7 | –1.02875 |
| ELOVL1 | ELOVL Fatty Acid Elongase 1 | –1.02678 |
| CAT | Catalase | –1.01705 |
| SIGMAR1 | Sigma Non-Opioid Intracellular Receptor 1 | –1.00092 |
Figure 6Viability of adherent cells was highly decreased by inhibition of cholesterol pathway
(A) The significantly enriched genes in the steroid biosynthesis signal pathway. Red boxes indicate the significantly increased genes, and blue boxes indicate the significantly decreased genes. (B) Viability of adherent cells was highly decreased by simvastatin treatment. Cells were plated into 6-well plates at a density of 3 × 105 cells per well and treated with 10 μM simvastatin. Viability of cells was assessed by trypan blue exclusion test at the indicated hours. *p < 0.05, **p < 0.01, ***p < 0.001; two-tailed Student’s t-test.
Figure 7Venn diagram showing comparison of up- and down-regulated genes between MDA-MB-468 suspension cells and CTCs vs primary breast tumors
Genes showing p-value < 0.05 and log2 fold change > 1 in suspension cells were compared with up- and down-regulated genes in CTCs vs primary breast tumors.